US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

129.52

+1.501.17%

Volume:24.11K

Turnover:3.12M

Market Cap:538.80M

PE:6.72

High:130.28

Open:128.45

Low:128.45

Close:128.02

52wk High:131.68

52wk Low:90.01

Shares:4.16M

Float Shares:4.16M

Volume Ratio:1.12

T/O Rate:0.58%

Dividend:1.06

Dividend Rate:0.82%

EPS(TTM):19.29

EPS(LYR):21.73

ROE:23.89%

ROA:0.60%

PB:1.62

PE(LYR):5.96

Loading ...

Overview Company News Filings

Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets

Eli Lilly (LLY) Says Zepbound Cuts Healthcare Costs For Adults Over 55

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)

China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs

HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million

Abbott Laboratories' Stroke Treatment Device Receives CE Mark

MT Newswires Live

Abbott - to Expand Amulet 360 Use Across Europe in Coming Weeks

THOMSON REUTERS

Abbott - First European Cases Using Amulet 360 Completed in Germany and Denmark

THOMSON REUTERS

Abbott's Next-Generation Amulet 360™ Device Receives Ce Mark to Treat People with Atrial Fibrillation at Risk of Stroke

THOMSON REUTERS

Abbott Wins CE Mark for Amulet 360 Left Atrial Appendage Occluder in Europe

Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints

China Approves J&J's Oral Psoriasis Pill, Says Drugmaker

Johnson & Johnson Says Oral Icotrokinra Approved in China for Moderate-to-Severe Plaque Psoriasis - Statement

THOMSON REUTERS

AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients

MT Newswires Live

AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial

AbbVie Seeks EMA Approval for Skyrizi Subcutaneous Induction in Crohn’s Disease

Amgen - Tezspire Safety Profile Consistent with Approved Indications

THOMSON REUTERS

Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/PJP/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PJP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PJP\",,,,,undefined,":{"symbol":"PJP","market":"US","secType":"STK","nameCN":"INVESCO PHARMACEUTICALS ETF","latestPrice":129.52,"timestamp":1788370989790,"preClose":128.02,"halted":0,"volume":24114,"delay":0,"changeRate":0.011716919231370098,"floatShares":4160000,"shares":4160000,"eps":19.286062,"marketStatus":"Trading","change":1.5,"latestTime":"09-02 13:45:59 EDT","open":128.45,"high":130.28,"low":128.45,"amount":3117724.3797000004,"amplitude":0.014295,"askPrice":129.72,"askSize":100,"bidPrice":129.61,"bidSize":200,"shortable":3,"etf":1,"ttmEps":19.286062,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":128.02,"sharesOutstanding":3870000,"nav":127.38971,"aum":533762884.9,"dividendRate":0.008184,"bidAskSpread":0.000948,"postHourTrading":{"tag":"盘后","latestPrice":128.02,"preClose":128.02,"latestTime":"19:30 EDT","volume":21,"amount":2677.21,"timestamp":1788305400491,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.116112,"impliedVol":0.1163,"impliedVolPercentile":0.5635},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PJP\",,,,,undefined,":{"symbol":"PJP","floatShares":4160000,"roa":"0.60%","roe":"23.89%","lyrEps":21.734944,"volumeRatio":1.116112,"shares":4160000,"dividePrice":1.06,"high":130.28,"amplitude":0.014295,"preClose":128.02,"low":128.45,"week52Low":90.01,"pbRate":"1.62","psRate":"106.30","week52High":131.675,"institutionHeld":0.824,"latestPrice":129.52,"committee":0.333333,"eps":19.286062,"divideRate":0.008184,"volume":24114,"delay":0,"ttmEps":19.286062,"open":128.45,"prevYearClose":104.54,"prevWeekClose":127.2607,"prevMonthClose":127.49,"prevQuarterClose":118.4468,"fiveDayClose":130.0585,"twentyDayClose":124.79,"sixtyDayClose":110.4415},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PJP\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"PJP","amount":0.27334,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"INVESCO PHARMACEUTICALS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"PJP","amount":0.30902,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"INVESCO PHARMACEUTICALS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"PJP","amount":0.24629,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"INVESCO PHARMACEUTICALS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"PJP","amount":0.23633,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"INVESCO PHARMACEUTICALS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PJP","amount":0.26679,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"INVESCO PHARMACEUTICALS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PJP\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-30","value":0.10701,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.20736,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-31","value":0.03683,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-30","value":0.15586,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-29","value":0.12281,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PJP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PJP\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662084187","title":"Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084187","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084187?lang=en_us&edition=fundamental","pubTime":"2026-08-28 00:31","pubTimestamp":1787848308,"startTime":"0","endTime":"0","summary":"Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has started a new Phase 1 trial called “A Phase 1, Open-La...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/amgens-amg-691-phase-1-trial-targets-key-growth-in-asian-markets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBE","LU0058720904.USD","LU1571399168.USD","BK4139","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0109394709.USD","IBBQ","BK4533","LU0122379950.USD","BBC","LU2468319806.SGD","LU2112291526.USD","BK4588","LU0320765992.SGD","LU1057294990.SGD","IE0009355771.USD","BK4566","IE00B4R5TH58.HKD","AMGN","TBXU","BK4599","PJP","SG9999001440.SGD","BIB","LU0889565916.HKD","LU2089984988.USD","LU1061106388.HKD","LU2242652126.USD","IBB","BK4581","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4585","LU1983299246.USD","LU0289739699.SGD","LU0868494617.USD","LU1023059063.AUD","BBH","BK4534","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662812320","title":"Eli Lilly (LLY) Says Zepbound Cuts Healthcare Costs For Adults Over 55","url":"https://stock-news.laohu8.com/highlight/detail?id=2662812320","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662812320?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:29","pubTimestamp":1787844592,"startTime":"0","endTime":"0","summary":"Eli Lilly (NYSE: LLY) reported new independent real-world evidence that its obesity treatment Zepbound (tirzepatide) is linked to lower overall healthcare costs for adults over 55 with obesity.\nThe analysis indicates these cost savings appear as early as 12 months after starting Zepbound treatment in this older patient group.\nThe findings focus on total healthcare spending rather than drug costs alone and suggest a potential economic advantage for Zepbound in routine clinical use.\nThe...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/285467-main-header/1756214710679","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/285467-main-header/1756214710679"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-lly/eli-lilly/news/eli-lilly-lly-says-zepbound-cuts-healthcare-costs-for-adults","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-lly/eli-lilly/news/eli-lilly-lly-says-zepbound-cuts-healthcare-costs-for-adults","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LLII","LU0345770993.USD","SGXZ81514606.USD","IE00BK4W5L77.USD","LU1323610961.USD","LU1712237335.SGD","LU1989771016.USD","IE00B4JS1V06.HKD","IE0004445015.USD","BK4007","PJP","LU2471134796.USD","LU0964807845.USD","LU1868837300.USD","LU2211815571.USD","ILDR","FHLC","LU0198837287.USD","LU2746668974.SGD","IE0002141913.USD","LU0133085943.USD","LU1629891620.HKD","LU1979441026.SGD","SG9999018857.SGD","LU0256863902.USD","LLYZ","LU1551013342.USD","LU2237443622.USD","LU0708995401.HKD","FTXH","LU0114720955.EUR","BK4516","IE00BKPKM429.USD","LU1814569148.SGD","LU2756315318.SGD","CURE","LU0225283273.USD","LU1691799644.USD","LU1145028129.USD","LU1280957306.USD","LU2552382132.HKD","LU0820561909.HKD","SG9999014880.SGD","LU2063271972.USD","HRTS","LU2468319806.SGD","LU0823434583.USD","SG9999014914.USD","LU0122379950.USD","LU2237438978.USD","IE00BFSS7M15.SGD","IE00B4R5TH58.HKD","LU2602419157.SGD","LU0787776722.HKD","LU2265009873.SGD","LU0456855351.SGD","SGXZ51526630.SGD","IE0001KFT4U8.USD","LU0061475181.USD","IE00BJLML261.HKD","LU0882574139.USD","LU1232071149.USD","LU2168564065.EUR","LU2112291526.USD","LU1974910355.USD","IE00B775H168.HKD","LU1093756168.USD","PPH","LU0823416689.USD","LU1069344957.HKD","LU2491049909.HKD","LU2461242641.AUD","LU0823434740.USD","SG9999015945.SGD","LU1291159041.SGD","LU0109391861.USD","LU2237443978.SGD","AGNG","LU1093756325.SGD","SG9999001176.SGD","IE00BJJMRX11.SGD","LU0210536198.USD","LU2361044865.SGD","LU0689472784.USD","LU0323591593.USD","LU1868837136.USD","LU2237443465.HKD","LU2168563687.JPY","LU2417539215.USD","LU1057294990.SGD","LU0106261372.USD","SG9999001176.USD","LU0289739699.SGD","LU0683600562.USD","IE00BFTCPJ56.SGD","LU0174119429.USD","LU2552382058.USD","LLY","LU2089283258.USD","IE00B7KXQ091.USD","IE00B2B36J28.USD","BK4533","LU2361044949.HKD","LU0466842654.USD","LU0354030511.USD","ELIL","IE0004445239.USD","IE00BKDWB100.SGD","SG9999015978.USD","LU1064131342.USD","LU0943347566.SGD","IE00BWXC8680.SGD","LU0158827948.USD","LU0820561818.USD","IE00BN29S564.USD","LU2491050071.SGD","MEDI","LU0353189680.USD","BK4588","LU2087625088.SGD","IE00B1XK9C88.USD","LU2746668461.USD","BK4581","LU1868836914.USD","LU1917777945.USD","LU2552382215.SGD","LU1720051017.SGD","LU0353189763.USD","SGXZ99366536.SGD","JDOC","IE00BFSS8Q28.SGD","LU1023059063.AUD","LU1548497426.USD","LU2108987350.USD","LU2357305700.SGD","LU0345770308.USD","LU2089284900.SGD","SGXZ57979304.SGD","LU0471298694.HKD","OZEM","LU2023250504.SGD","LU2750360641.GBP","LU2264538146.SGD","LU2271345857.HKD","LU2750360997.AUD","RXL","LU0882574055.USD","LU0432979614.USD","IE0009355771.USD","LU2168564495.EUR","TRUH","LU0006306889.USD","SGXZ31699556.SGD","LU1035775433.USD","LU0238689110.USD","LU2471134523.USD","WDNA","TMED","LU0109394709.USD","LU0316494557.USD","LU0417517546.SGD","SG9999013999.USD","LU2028103732.USD","LU1551013425.SGD","IE00BJJMRZ35.SGD","LU1868836591.USD","SG9999015952.SGD","LU0203202063.USD","LU1983299246.USD","LU2168564149.EUR","LU2213496289.HKD","THNR","LU0672654240.SGD","LU1623119135.USD","LU1868836757.USD","LU2491050154.USD","LU2360106947.USD","LU0266013472.USD","GB00BDT5M118.USD","IE0005OL40V9.USD","LU0640476718.USD","LU0786609619.USD","LU2462591350.SGD","LU2361045086.USD","BK4599","LU2237443382.USD","SG9999014906.USD","SG9999015986.USD","CANC","LU2896262040.SGD","LU0320765992.SGD","LU0385154629.USD","LU0320765059.SGD","LU2168564222.USD","LU2089984988.USD","LU2756315664.SGD","GDOC","SG9999018865.SGD","LU1366192091.USD","LU2106854487.HKD","BK4534","LU0256863811.USD","LU1061106388.HKD","IHE","LU2471134879.HKD","LU2462157665.USD","IE00BJJMRY28.SGD","LU0234572021.USD","LU1720051108.HKD","LU0158827781.USD","LU1267930730.SGD","MEDX","LU2324357040.USD","LU2456880835.USD","LU0096364046.USD","LU2236285917.USD","LU2237443549.SGD","IE00BJT1NW94.SGD","LU0079474960.USD","SG9999014898.SGD","LU1127390331.HKD","LLYX","LU0354030438.USD","IE00BK4W5M84.HKD","LU2471134952.CNY","LU0058720904.USD","LU2111349929.HKD","LU2023250330.USD","LU0094547139.USD","LU1804176565.USD","ELIS","LU0203201768.USD","LU0889565916.HKD","LU2023251221.USD","IE00B1BXHZ80.USD","SG9999017495.SGD","LU0097036916.USD","LU1988902786.USD","LU0820562030.AUD","LU0471298777.SGD","BK4585","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662813780","title":"Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662813780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662813780?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:20","pubTimestamp":1787844046,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Verrica Pharmaceuticals (VRCA) and Amgen (AMGN). Verrica Pharmace...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-verrica-pharmaceuticals-vrca-and-amgen-amgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBBQ","IE00BJT1NW94.SGD","LU1057294990.SGD","LU2468319806.SGD","LABU","AMGN","XLV","LU2089984988.USD","IBB","LU0109394709.USD","BIB","HCSG","BBH","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0122379950.USD","LU2112291526.USD","LU0058720904.USD","LU0868494617.USD","LU1571399168.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","BK4137","PBE","LU0029874061.USD","LU0128526141.USD","BK4581","BK4007","VRCA","TBXU","IE0009355771.USD","IE00B4R5TH58.HKD","BK4599","LU0889565916.HKD","BK4534","BK4139","XBI","LU2242652126.USD","BK4533","PJP","IE0002141913.USD","IE00B2B36J28.USD","LU1061106388.HKD","LU1983299246.USD","LU0289739699.SGD","BK4585","SG9999001440.SGD","BK4566","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662108530","title":"China's HBM Holdings H1 Revenue Rises on Progress on Mid-Late Clinical Stage Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2662108530","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662108530?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:10","pubTimestamp":1787839834,"startTime":"0","endTime":"0","summary":"China's HBM Holdings H1 revenue rises on progress on mid-late clinical stage programsOverviewChina biopharma firm's half-year revenue rose yr/yr to $122.5 mlnNet profit for the period declined compare","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0PB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","LU0061475181.USD","BK4007","LU0225771236.USD","LU2125154935.USD","PPH","LU0310800379.SGD","RXL","SG9999015952.SGD","FHLC","LU1057294990.SGD","LU0661504455.SGD","LU1989771016.USD","TRUH","IE0000B7K699.USD","IE00BVYPNW00.USD","LU0868494708.USD","FTXH","GLAM","IE00BLSP4239.USD","IHE","PJP","MEDX","VHT","LU0237698245.USD","LU0985320562.USD","AGNG","IYH","BMY","LU2237443622.USD","02142","02616","LU1718418525.SGD","IXJ","LU1037948541.HKD","LU0289739343.SGD","ABBV","LU1023059063.AUD","IE000BZT7R73.USD","BK1161","BK4588","LU0256863811.USD","JDOC","LU1267930573.SGD","XLV","LU0708994859.HKD","LU2237443465.HKD","LU1868836591.USD","LU1670711123.USD","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662084083","title":"HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662084083","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662084083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:01","pubTimestamp":1787839287,"startTime":"0","endTime":"0","summary":"HBM Holdings FY26 H1 profit falls 11.16% to US$ 64.85 million; revenue rises 20.9% to US$ 122.49 millionHBM Holdings posted revenue of US$122.49 million for the six months ended June 30, 2026, up 20.9","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL77D5HK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","PJP","BBH","LU0868494617.USD","BK4139","LU1983299246.USD","LU2112291526.USD","BK4534","BK4588","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4533","LU2242652126.USD","02142","IE00BJJMRZ35.SGD","LU1061106388.HKD","IBB","LU1571399168.USD","LU2242646821.SGD","LU0058720904.USD","SG9999001440.SGD","PBE","BK1574","LU0889565916.HKD","LU1023059063.AUD","BK1583","LU2089984988.USD","IBBQ","TBXU","LU0122379950.USD","IE00BJT1NW94.SGD","BIB","IE0002141913.USD","BK4585","AMGN","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4566","LU2468319806.SGD","LU1057294990.SGD","LU0109394709.USD","BK4599","BK4581","BK1161","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662833310","title":"Abbott Laboratories' Stroke Treatment Device Receives CE Mark","url":"https://stock-news.laohu8.com/highlight/detail?id=2662833310","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662833310?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:35","pubTimestamp":1787837729,"startTime":"0","endTime":"0","summary":"Abbott Laboratories  has received the CE Mark for its stroke treatment device Amulet 360 Left Atrial Appendage Occluder, the company said Thursday.The device is designed to reduce risk of stroke in patients with atrial fibrillation not caused by a heart valve issue, Abbott said.The CE Mark approval for the device was supported by recent clinical data that showed Amulet 360 met benchmarks for safety and effectiveness, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4566","IE00BJJMRZ35.SGD","LU0070302665.USD","LU0114720955.EUR","LU1989763690.USD","BK4533","BK4568","LU1691799644.USD","SG9999004303.SGD","LU2133065610.SGD","ABT.AU","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0320765489.SGD","LU2237957902.USD","BK4592","SG9999002224.SGD","LU1023059063.AUD","LU2237957811.SGD","LU2324357040.USD","BK4581","LU0266013472.USD","LU0432979614.USD","SGXZ41872573.SGD","LU0208291251.USD","BK4585","IE00B2B36J28.USD","LU0882574055.USD","LU2211815571.USD","LU1057294990.SGD","PJP","LU1721429741.USD","LU1061106388.HKD","LU2112291526.USD","LU0122379950.USD","LU0868494617.USD","IHI","BK4082","TMED","LU1989763427.SGD","BK4588","LU1721429402.USD","LU0211331839.USD","SG9999002232.USD","LU0170899867.USD","IE0009355771.USD","LU2089984988.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","ABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662735700","title":"Abbott - to Expand Amulet 360 Use Across Europe in Coming Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2662735700","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662735700?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:03","pubTimestamp":1787835797,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1H1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765489.SGD","SGXZ41872573.SGD","LU0070302665.USD","LU0234572021.USD","LU0882574055.USD","LU1721429741.USD","IE00BFTCPJ56.SGD","LU2133065610.SGD","LU0432979614.USD","LU0868494617.USD","LU0289739699.SGD","IE00BJT1NW94.SGD","BK4588","LU1721429402.USD","IE00BJJMRZ35.SGD","LU0266013472.USD","IE0009355771.USD","LU1989763427.SGD","LU0122379950.USD","BK4504","LU1061106388.HKD","LU0211331839.USD","TMED","LU2324357040.USD","LU2468319806.SGD","LU2112291526.USD","LU0208291251.USD","LU0058720904.USD","BK4566","SG9999004303.SGD","IE00B4R5TH58.HKD","BK4533","LU2237957902.USD","PJP","BK4581","LU0170899867.USD","BK4082","IHI","BK4568","BK4592","IE0002141913.USD","IE00B2B36J28.USD","LU1057294990.SGD","SG9999002232.USD","LU1989763690.USD","LU0114720955.EUR","SG9999002224.SGD","LU2211815571.USD","ABT","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700741","title":"Abbott - First European Cases Using Amulet 360 Completed in Germany and Denmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662700741?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:03","pubTimestamp":1787835797,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1H1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2133065610.SGD","SGXZ41872573.SGD","SGXZ23171101.USD","LU0432979614.USD","LU0070302665.USD","SG9999002232.USD","LU1914381329.SGD","IHI","LU0114720955.EUR","LU2089984988.USD","LU1023059063.AUD","BK4533","IE00BJJMRZ35.SGD","LU2211815571.USD","IE00BFTCPJ56.SGD","LU1989763427.SGD","LU0266013472.USD","LU0170899867.USD","IE0009355771.USD","PJP","BK4082","LU2237957902.USD","LU1061106388.HKD","BK4568","LU2468319806.SGD","IE00BJT1NW94.SGD","LU2237957811.SGD","LU0320765489.SGD","LU1691799644.USD","BK4588","LU1057294990.SGD","SG9999002224.SGD","ABT","LU0211331839.USD","TMED","LU0868494617.USD","BK4566","LU0058720904.USD","BK4585","SG9999004303.SGD","BK4581","IE00B2B36J28.USD","LU0208291251.USD","LU1989763690.USD","BK4504","LU0234572021.USD","LU1721429402.USD","LU0122379950.USD","LU2324357040.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700732","title":"Abbott's Next-Generation Amulet 360™ Device Receives Ce Mark to Treat People with Atrial Fibrillation at Risk of Stroke","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662700732?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:03","pubTimestamp":1787835797,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1H1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4504","LU0234572021.USD","LU0058720904.USD","SG9999002224.SGD","LU0070302665.USD","LU1721429402.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU1721429741.USD","LU2211815571.USD","BK4082","BK4568","IHI","LU0122379950.USD","SGXZ41872573.SGD","LU2468319806.SGD","LU0114720955.EUR","LU1989763690.USD","LU2112291526.USD","BK4588","LU0882574055.USD","LU1057294990.SGD","IE0009355771.USD","BK4566","IE00B4R5TH58.HKD","LU1691799644.USD","LU2133065610.SGD","LU2324357040.USD","LU2237957902.USD","PJP","BK4592","LU1061106388.HKD","LU2089984988.USD","TMED","LU0266013472.USD","BK4581","LU0432979614.USD","IE00BFTCPJ56.SGD","LU0320765489.SGD","SG9999004303.SGD","LU0289739699.SGD","LU0868494617.USD","ABT","LU0170899867.USD","LU1023059063.AUD","LU2237957811.SGD","SG9999002232.USD","LU1914381329.SGD","IE00BJT1NW94.SGD","LU0208291251.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662007837","title":"Abbott Wins CE Mark for Amulet 360 Left Atrial Appendage Occluder in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2662007837","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662007837?lang=en_us&edition=fundamental","pubTime":"2026-08-27 21:02","pubTimestamp":1787835728,"startTime":"0","endTime":"0","summary":"Abbott wins CE Mark for Amulet 360 left atrial appendage occluder in EuropeAbbott won CE Mark for its next-generation Amulet 360 left atrial appendage occluder for non-valvular AFib patients at stroke","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL8znFky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0122379950.USD","LU1023059063.AUD","LU1721429402.USD","ABT","IE00BJT1NW94.SGD","LU0432979614.USD","SG9999002224.SGD","BK4568","BK4082","LU2237957902.USD","LU0208291251.USD","IE00B2B36J28.USD","LU0289739699.SGD","LU2324357040.USD","LU1914381329.SGD","BK4566","LU1057294990.SGD","LU0170899867.USD","LU2237957811.SGD","TMED","IE0009355771.USD","LU1989763427.SGD","SG9999004303.SGD","LU2211815571.USD","LU0058720904.USD","IE00B4R5TH58.HKD","BK4533","BK4581","PJP","LU0320765489.SGD","SG9999002232.USD","BK4588","SGXZ41872573.SGD","LU1691799644.USD","LU2468319806.SGD","LU0882574055.USD","LU0114720955.EUR","BK4592","LU1989763690.USD","LU2133065610.SGD","LU0211331839.USD","IE00BJJMRZ35.SGD","IHI","IE0002141913.USD","LU0234572021.USD","LU2089984988.USD","BK4585","LU2112291526.USD","LU1721429741.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662013447","title":"Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements","url":"https://stock-news.laohu8.com/highlight/detail?id=2662013447","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662013447?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:15","pubTimestamp":1787829352,"startTime":"0","endTime":"0","summary":"Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-crossing-trial-showed-meaningful-improvements-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029864427.USD","BBH","LU2242652126.USD","BK4588","LU0868494617.USD","LU2237443622.USD","LU0432979614.USD","BK4139","AMGN","IBBQ","LU1829250122.USD","BK4581","AZN","LU2468319806.SGD","BK4534","LU2417539215.USD","BK4007","IE00B3T34201.USD","LU2237443978.SGD","LU0128525929.USD","LU2242646821.SGD","BK4568","IE00B4R5TH58.HKD","LU1057294990.SGD","LU2237443382.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU2237443465.HKD","BIB","BK4533","TBXU","LU0122379950.USD","LU2462157665.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","PBE","PJP","LU0289739699.SGD","LU2456880835.USD","IE0009355771.USD","LU2236285917.USD","LU1023059063.AUD","AZNH","LU0708994859.HKD","LU1267930573.SGD","LU2089984988.USD","BK4566","BK4585","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708043","title":"China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708043","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708043?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:08","pubTimestamp":1787825320,"startTime":"0","endTime":"0","summary":"China's JW Therapeutics interim revenue rises 4.7% on Carteyva salesOverviewChina cell immunotherapy developer's interim revenue grew 4.7% yr/yr, driven by Carteyva salesGross profit margin improved t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","LU0395794307.EUR","BBH","LU0463099449.HKD","IBB","IBBQ","IE0004445239.USD","LU1934455277.USD","LU2237443382.USD","LU2237443978.SGD","LU2097828714.EUR","XLV","MEDX","LU1037948897.HKD","RXL","IE00BVYPNV92.GBP","02126","LU0868494617.USD","LU1934455863.HKD","IE000SO60NU8.SGD","IYH","IE00BN8TJ469.HKD","REGN","TRUH","FHLC","PJP","LU0859254822.USD","FTXH","LU1188198961.HKD","LU0310799852.SGD","CMI","AGNG","PPH","TBXU","LU0949170772.SGD","BK1574","GLAM","LU0943347566.SGD","VHT","688331","KURE","LU2362541513.USD","LU0708994859.HKD","MADE","LU1244550577.SGD","03692","01801","IXJ","JDOC","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662877754","title":"Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662877754","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662877754?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:15","pubTimestamp":1787822113,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 CROSSING trial of Tezspire in patients living with eosinophilic esop...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-report-crossing-trial-met-co-primary-and-secondary-endpoints-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZN","BBH","LU0029864427.USD","LU1023059063.AUD","PJP","LU1983299246.USD","BK4599","IBB","LU1267930573.SGD","LU2456880835.USD","PBE","LU2237443465.HKD","BK4533","LU0128525929.USD","BK4585","AMGN","LU1829250122.USD","BIB","LU0889565916.HKD","IE00BJT1NW94.SGD","LU2417539215.USD","LU1061106388.HKD","TBXU","IE0002141913.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00B3T34201.USD","LU2236285917.USD","LU2237443895.HKD","LU2237443978.SGD","BK4588","BK4568","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU2112291526.USD","LU2242646821.SGD","IBBQ","BK4007","LU0122379950.USD","AZNH","LU0289739699.SGD","BK4581","LU0432979614.USD","LU0058720904.USD","IE00B2B36J28.USD","LU2468319806.SGD","IE0009355771.USD","LU1571399168.USD","LU0868494617.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774764","title":"China Approves J&J's Oral Psoriasis Pill, Says Drugmaker","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774764","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662774764?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:47","pubTimestamp":1787820442,"startTime":"0","endTime":"0","summary":"China approves J&J's oral psoriasis pill, says drugmakerSHANGHAI, Aug 27 (Reuters)-Johnson & JohnsonJNJ.Nsaid on Thursday that its oral drug icotrokinra was approved in China for moderate-to-severe plaque psoriasis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O0QI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF631.EUR","PJP","RXL","LU0683600562.USD","IHE","VHT","XLV","LU0795875086.SGD","LU0795875169.SGD","LU1061106388.HKD","IE00BJJMRZ35.SGD","IE000MB6IJN5.SGD","FTXH","LU0689472784.USD","LU1032955483.USD","LU1057294990.SGD","LU1228905037.USD","LU1551013342.USD","LU1221951046.USD","BK4534","JDOC","LU0426412945.USD","LU2236285917.USD","LU0466842654.USD","GDOC","BK4588","BMED","LU0640476718.USD","LU2129689605.HKD","FHLC","IXJ","LU1059921491.USD","IE00B19Z3B42.SGD","LU0689626769.HKD","MEDX","IYH","LU1935042991.SGD","LU2756315318.SGD","LU1732799900.SGD","LU1162221912.USD","TRUH","IE00BLSP4239.USD","IE00BBT3K403.USD","IE00BKVL7J92.USD","LU1244550577.SGD","LU0162691827.USD","LU0820561909.HKD","LU1043141396.HKD","JNJ","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662477411","title":"Johnson & Johnson Says Oral Icotrokinra Approved in China for Moderate-to-Severe Plaque Psoriasis - Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2662477411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662477411?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:47","pubTimestamp":1787820442,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4N44O0QI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0640476718.USD","LU0943347566.SGD","LU1066051498.USD","RXL","FHLC","BK4568","XLV","TRUH","BMED","LU0994945656.USD","LU2347655156.SGD","IE00BVYPNV92.GBP","IYH","LU0053666078.USD","IXJ","LU1551013425.SGD","LU1032466523.USD","VHT","IE00BLSP4239.USD","BK4532","IE00BFXG1179.USD","LU2505996681.GBP","PJP","IE0002270589.USD","LU0882574055.USD","LU2129689514.USD","LU1196500208.SGD","IE0002141913.USD","BK4588","LU1244550494.USD","MEDX","SG9999001176.USD","JNJ","IE00BN8TJ469.HKD","IHE","IE00BDGV0183.EUR","JDOC","LU2471134523.USD","GDOC","FTXH","LU1506573853.SGD","IE00B42XCP33.USD","IE00BSNM7G36.USD","IE0009355771.USD","LU1894683264.USD","LU2896262040.SGD","LU1244550221.USD","LU2592432038.USD","IE000MB6IJN5.SGD","LU1066053197.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771175","title":"AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771175","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771175?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:24","pubTimestamp":1787819085,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Amgen  said Thursday their drug Tezspire met the primary endpoints of a Phase 3 trial treating eosinophilic esophagitis, a chronic inflammatory esophagus disorder.The medication met both primary endpoints by reducing tissue inflammation and easing swallowing difficulties at week 24 compared to a placebo, the companies said.The disease and symptom improvements were maintained through week 52 for both tested doses, they said.The companies also said the safety profile of the treatment during the study remained consistent with its previously approved uses.Shares of Amgen were down by over 1% in Thursday premarket activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TBXU","AZNH","IE00B4R5TH58.HKD","BK4534","LU2462157665.USD","LU2237443622.USD","LU2242652126.USD","LU0058720904.USD","LU0889565916.HKD","BBH","LU2242646821.SGD","BK4533","PJP","LU0708994859.HKD","BK4585","LU2089984988.USD","LU2237443465.HKD","LU1057294990.SGD","LU1061106388.HKD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","LU0128525929.USD","LU1267930573.SGD","BK4566","IE00BJT1NW94.SGD","LU2456880835.USD","IE00BFTCPJ56.SGD","LU0432979614.USD","LU1829250122.USD","BK4599","LU0029864427.USD","LU0310800379.SGD","AMGN","BIB","BK4581","IBBQ","AZN","IBB","LU0109394709.USD","LU2237443382.USD","LU0868494617.USD","LU1571399168.USD","IE00B2B36J28.USD","PBE","BK4007","LU2237443549.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662514775","title":"AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662514775","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662514775?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:40","pubTimestamp":1787812818,"startTime":"0","endTime":"0","summary":"UPDATE 3-AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trialAug 27 (Reuters)-AstraZenecaAZN.Lsaid on Thursday its asthma drug Tezspire met the main goals of a late-stage tria","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL6N44O0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1051770623.HKD","IBB","03165","LU1481600234.SGD","BIB","LU0997586432.USD","LU1153584641.USD","LU1571399168.USD","LU0345777659.USD","LU0997586515.USD","LU1119994496.HKD","LU1880407132.USD","LU1003077747.HKD","IE00BFTCPJ56.SGD","LU0052756011.USD","LU0738911758.USD","LU1267930490.SGD","LU2237443382.USD","AZN.UK","LU0661504455.SGD","LU0823434583.USD","LU1170363599.USD","LU1829250122.USD","LU0432979614.USD","LU2293690082.USD","LU0575583348.USD","LU0047473722.EUR","PBE","LU2242652126.USD","BBH","LU0792757196.USD","BK4588","BK4599","TBXU","LU0887340254.USD","LU1974910355.USD","LU0077335932.USD","LU1057294990.SGD","LU0266013472.USD","LU0122379950.USD","PJP","LU0310799852.SGD","AMGN","SGXZ57979304.SGD","LU0640478417.SGD","LU2237443622.USD","LU3187612489.SGD","REGN","IBBQ","LU0972486137.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662733417","title":"AbbVie Seeks EMA Approval for Skyrizi Subcutaneous Induction in Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2662733417","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662733417?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:01","pubTimestamp":1787810517,"startTime":"0","endTime":"0","summary":"AbbVie seeks EMA approval for Skyrizi subcutaneous induction in Crohn’s diseaseAbbVie filed with the EMA seeking approval for SKYRIZI subcutaneous induction in adults with moderately to severely activ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL4xK88y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGNG","LU0965509010.AUD","LU2237443895.HKD","LU1670628061.USD","LU1093756325.SGD","LU2023251221.USD","LU0198837287.USD","LU1934455277.USD","LU1236620834.HKD","IE00BGHQF631.EUR","XLV","LU1718418525.SGD","RXL","LU1496350502.SGD","LU1003077747.HKD","LU1934455863.HKD","BK4566","LU0882574055.USD","LU1989771016.USD","SG9999011175.SGD","FHLC","LU0472753341.HKD","LU2087621335.USD","SG9999001440.SGD","LU1244550221.USD","LU0861579265.USD","PJP","IXJ","LU1923622614.USD","BK4559","PPH","IE0002270589.USD","GLAM","TRUH","JDOC","SG9999015945.SGD","ABBV","LU1037948897.HKD","LU2129689514.USD","MEDX","LU0708994859.HKD","IYH","LU0417517546.SGD","FTXH","IE00BFTCPJ56.SGD","VHT","LU0320765646.SGD","LU2468319806.SGD","LU2433249047.HKD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778025","title":"Amgen - Tezspire Safety Profile Consistent with Approved Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778025?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:00","pubTimestamp":1787810401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA3XV48Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBBQ","LU1023059063.AUD","LU0868494617.USD","BBH","BK4599","LU2242646821.SGD","BK4585","BIB","IE00BJJMRZ35.SGD","LU2112291526.USD","LU0109394709.USD","LU2468319806.SGD","IE0002141913.USD","BK4588","AMGN","LU2242652126.USD","LU0889565916.HKD","LU1057294990.SGD","IE0009355771.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4533","LU1571399168.USD","PBE","BK4581","BK4534","LU0320765992.SGD","IE00BFTCPJ56.SGD","PJP","SG9999001440.SGD","IE00BJT1NW94.SGD","LU1983299246.USD","IBB","LU0122379950.USD","BK4566","LU2089984988.USD","LU0289739699.SGD","LU0058720904.USD","TBXU","LU1061106388.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662728778","title":"Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662728778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662728778?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:00","pubTimestamp":1787810401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA3XV48Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","PJP","BBH","LU0868494617.USD","BK4139","LU1983299246.USD","LU2112291526.USD","BK4534","BK4588","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4533","LU2242652126.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","IBB","LU1571399168.USD","LU2242646821.SGD","LU0058720904.USD","SG9999001440.SGD","PBE","LU0889565916.HKD","LU1023059063.AUD","LU2089984988.USD","IBBQ","TBXU","LU0122379950.USD","IE00BJT1NW94.SGD","BIB","IE0002141913.USD","BK4585","AMGN","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4566","LU2468319806.SGD","LU1057294990.SGD","LU0109394709.USD","BK4599","BK4581","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":5,"totalSize":216,"code":"91000000","status":"200"}]}}